Keywords: acadia, acp-103, misses, ph, ii, endpoint, usa-based
Acadia's ACP-103 misses Ph II endpoint
Article | 12 December 2005
USA-based Acadia Pharmaceuticals says that its lead drug candidate ACP-103 failed to achieve a significant reduction of haloperidol-induced akathisia, a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Elan puts up formal "for sale" notice
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
